Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann–Pick disease type B (acid sphingomyelinase deficiency)-Reference-Cited by-同舟云学术

Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann–Pick disease type B (acid sphingomyelinase deficiency)

Published:2016-01 Issue:1 Volume:18 Page:34-40
ISSN:1098-3600
Container-title:Genetics in Medicine
language:en
Short-container-title:Genetics in Medicine

Author:

McGovern Margaret M.,Wasserstein Melissa P.,Kirmse Brian,Duvall W. Lane,Schiano Thomas,Thurberg Beth L.,Richards Susan,Cox Gerald F.

Publisher

Elsevier BV

Subject

Genetics (clinical)

Link

http://www.nature.com/articles/gim201524.pdf

Reference29 articles.

1. Niemann-Pick disease types A and B: acid sphingomyelinase deficiencies.;Schuchman,2013

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maladies de Niemann-Pick ou déficits en sphingomyélinase acide (ASMD) : présentations cliniques, actualités thérapeutiques et perspectives;La Revue de Médecine Interne;2024-06

2. Regulatory news: Olipudase alfa‐rpcp (Xenpozyme™) for treatment of non‐central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients—FDA Approval summary;Journal of Inherited Metabolic Disease;2024-05-21

3. Overview of clinical, molecular, and therapeutic features of Niemann–Pick disease (types A, B, and C): Focus on therapeutic approaches;Cell Biochemistry and Function;2024-05-07

4. The Genetic Basis, Lung Involvement, and Therapeutic Options in Niemann–Pick Disease: A Comprehensive Review;Biomolecules;2024-02-11

5. Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial;Orphanet Journal of Rare Diseases;2023-12-02